numbers of double-sorted HSC from Npm1 þ / þ and Npm1 þ /À mice (CD45.1 þ CD45.2 þ ) were transplanted into lethally irradiated C57BL/6 (CD45.2) recipients together with competitor cells (CD45.2). Short-term (2 months) and long-term (4 months) competitive repopulating capability was studied by monitoring peripheral blood donor chimerism of recipient mice by flow cytometry. Mice transplanted with Npm1 þ /À HSC exhibited markedly lower engraftment than the recipients of Npm1 þ / þ HSC as measured by total chimerism (threefold; Figure 2a , Po0.03). The percentage total and myeloid chimerism in individual transplanted mice did not differ significantly at 2 and 4 months (data not shown). We also quantified donor chimerism in the bone marrow of the recipient mice 4 months after transplantation (Figure 2b ). Similar to the results in the peripheral blood, the competitive repopulating ability of the HSC from Npm1 þ /À mice was significantly reduced (8.5-fold; Figure 2b , Po0.02) in the bone marrow of the recipient mice. Although the engraftment potential of Npm1 þ /À HSC was reduced, we did not observe any effects on the composition of donor-derived mature hematopoietic cells in the peripheral blood of recipient mice (Supplementary Figure 5) . Thus, the level of NPM1 expression has a direct effect on HSC repopulating ability in vivo, but has no effect on hematopoietic fate commitment.
numbers of double-sorted HSC from Npm1 þ / þ and Npm1 þ /À mice (CD45.1 þ CD45.2 þ ) were transplanted into lethally irradiated C57BL/6 (CD45.2) recipients together with competitor cells (CD45.2). Short-term (2 months) and long-term (4 months) competitive repopulating capability was studied by monitoring peripheral blood donor chimerism of recipient mice by flow cytometry. Mice transplanted with Npm1 þ /À HSC exhibited markedly lower engraftment than the recipients of Npm1 þ / þ HSC as measured by total chimerism (threefold; Figure 2a , Po0.03). The percentage total and myeloid chimerism in individual transplanted mice did not differ significantly at 2 and 4 months (data not shown). We also quantified donor chimerism in the bone marrow of the recipient mice 4 months after transplantation ( Figure 2b ). Similar to the results in the peripheral blood, the competitive repopulating ability of the HSC from Npm1 þ /À mice was significantly reduced (8.5-fold; Figure 2b , Po0.02) in the bone marrow of the recipient mice. Although the engraftment potential of Npm1 þ /À HSC was reduced, we did not observe any effects on the composition of donor-derived mature hematopoietic cells in the peripheral blood of recipient mice (Supplementary Figure 5) . Thus, the level of NPM1 expression has a direct effect on HSC repopulating ability in vivo, but has no effect on hematopoietic fate commitment.
In summary, our Npm1 þ /À mouse model indicates that NPM1 has a role in maintaining HSC number and in preserving the functional integrity of these cells in the context of competitive transplantation. However, it does not appear to have a role in regulating HSC differentiation. Npm1 haploinsufficiency did not result in significant alterations in mature blood cell numbers or significant dysplasia in our mice. These results are at some variance with a previous report, in which Npm1 heterozygosity was associated with an MDS-like phenotype in older (6-10 months) mice. 4 We cannot completely exclude the possibility that the different techniques used to generate these mutant mice may explain the differences in our results; however, both models are associated with homozygous null embryonic lethality as well as decreased Npm1 mRNA (data not shown) and protein levels in Npm1 þ /À mice. Our study did use mice in which the targeted Npm1 allele was functionally eliminated by a single-gene trap event in the NPM1 locus between exons 7 and 8 (genetic background 129/SvEvBrd Â C57BL/6J), whereas in the previous study exons 2-7 were replaced by green fluorescent protein cassette introducing the stop codon after exon 2 (genetic background 129/Sv Â C57BL/6). Minor genetic variability between the two different substrains used in these studies (129/Sv vs 129/SvEvBrd) might also influence their respective phenotypes. 7 Although we have no definitive explanation for the difference in phenotypes, only our study directly assessed HSC function. We speculate that the increased number of HSC in Npm þ /À mice could be an important early step in myeloid pathogenesis, as these HSC could provide a milieu in which additional genetic events might occur, thereby increasing the susceptibility to subsequent development of MDS or myeloid leukemia. Indeed, prior studies have demonstrated that transgenic Em-myc overexpression in the Npm1 þ /À mutant setting can facilitate AML development. 4 However, these data also indicate that loss of NPM1 function alone is not sufficient to result in increased development of hematological malignancies, which suggests that other cooperating lesions are likely necessary for disease pathogenesis. Further studies focused on understanding the interactions between Npm1 and other genes associated with MDS or AML progression will help to identify these cooperating events.
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The authors declare no conflict of interest. 3, 4 Consequences of the long-term effects of continuous immunomodulation with lenalidomide are unknown. This is particularly relevant in patients with low-risk IPSS del(5q) MDS who may be exposed to this therapy for several years. Disease progression and karyotypic evolution in del(5q) patients treated with lenalidomide have been described recently; 5 however, a formal link to lenalidomide treatment is not evident. Emerging data that primitive stem cells harboring del(5q) might survive even in patients in complete cytogenetic remission 6 question the therapeutic strategy of unlimited lenalidomide therapy. Furthermore, there is limited evidence that discontinuation of lenalidomide may lead to long-term transfusion freedom. 7 Therefore, we evaluated the safety and efficacy of limited exposure duration to lenalidomide in patients achieving transfusion independence. We assessed the long-term outcome of these patients, as well as duration of transfusion independence and cytogenetic remission, in order to explore the correlation between the minimum exposure of lenalidomide and transfusion-free intervals. Between December 2003 and January 2010, 27 patients with transfusion-dependent low-and intermediate-1-risk del(5q) MDS were treated with lenalidomide at Katholisches Klinikum Duisburg, King's College London, Heinrich-Heine-University Dü sseldorf and Technische Universität Dresden, and interrupted or discontinued treatment after becoming transfusion independent. Reasons for discontinuation of lenalidomide were attempt to reduce long-time drug exposure after achieving hematologic responses (n ¼ 5) or complete cytogenetic (n ¼ 9) remission, end of drug supply within the clinical-study protocol (n ¼ 8), intolerable side effects (n ¼ 3) and patient's withdrawal of consent (n ¼ 2). Treatment was performed within clinical trial protocols conducted according to the Declaration of Helsinki. All patients gave informed consent. Transfusion independence was counted from the day of the next anticipated transfusion, according to previous transfusion frequency. Complete cytogenetic remission (CCyR) meant absence of any del(5q) karyotype and any other karyotypic abnormalities. Partial cytogenetic remission (PCyR) was defined as reduction of del(5q) metaphases by at least 50%, but less than 100%. All patients started lenalidomide treatment at 10 mg p.o. either daily or for 21 consecutive days out of 28 days. Dose reductions were performed for both non-hematologic toxicities and hematological toxicities.
A total of 10 patients were male, 17 female, all caucasian. Median age was 69 years. Median time from diagnosis to treatment was 20 months (range, 1-120). Twenty-one patients had MDS with isolated del(5q) according to the WHO classification, 3 had RCMD and additional chromosomal abnormalities, and 3 had RAEB-1. Treatment duration varied from 29 to 2162 days (median, 361 days). The median follow-up for all patients is 48 months (range, 29-86). In all, 92% of patients achieved a cytogenetic remission: 16 patients (59%) achieved a CCyR (median duration of treatment 363 days; range, 180-2162), 9 patients (33%) achieved a PCyR (median duration of treatment 154 days; range, 29-404), and 2 patients (7.5%) had no reduction in abnormal cytogenetic metaphases (treatment duration 102 and 359 days). Of the 16 patients who achieved CCyR, 12 (75%) remain transfusion independent, whereas 6 of 11 patients (55%) in less than CCyR have relapsed ( Figure 1 , P ¼ 0.09). Three of those patients received lenalidomide for less than 6 months. Eight patients were administered lenalidomide at least 6 months beyond achievement of CCyR. Seven of those eight patients (88%) remain transfusion independent for a median follow-up time of 54 months (range, 27-96) (Figure 2 ). Three patients had additional cytogenetic abnormalities to del(5q), one of whom relapsed with transfusion dependence. Notably, one patient with a complex karyotype at the time of treatment initiation remains in CCyR at month 76 of follow-up, 12 months after stopping lenalidomide. Three patients had RAEB-1 at the commencement of lenalidomide therapy. One patient achieved transfusion independence without cytogenetic remission, and later progressed to acute myeloid leukemia (AML). The second patient remains in PCyR and ongoing transfusion independence after stopping lenalidomide. The third patient had a 9-year history of refractory anemia, and started lenalidomide in 2004 at a blast count of 8%. She went into CCyR within 6 months but developed follicular lymphoma of the skin at month 9. She discontinued lenalidomide treatment and underwent six cycles of rituximab, fludarabine and cyclophosphamide therapy. This patient remained in CCyR for 76 months. Undergoing a routine follow-up bone marrow biopsy at that time and being even transfusion independent, she developed a complex karyotype without del(5q) chromosomal abnormality, and is now scheduled for allogeneic stem cell transplantation. Three patients who relapsed with transfusion dependence were rechallenged with lenalidomide. All of them responded to reintroduction of lenalidomide intervention; Letters to the Editor however, two have lost the second response. A total of three patients underwent disease progression (two described above). The third patient achieved complete cytogenetic remission, continued lenalidomide for 6 months, but progressed thereafter to RAEB-2.
Current recommendations state that treatment with lenalidomide in del(5q) MDS should be continued until disease progression. 4 The question whether interruption of lenalidomide treatment for patients in remission would be beneficial has never been formally addressed. This concept is appealing for several reasons: first, it would reduce costs and side effects. Second, the progression to AML in del(5q) disease is not entirely understood. Reducing lenalidomide exposure would prevent a notional selective pressure of the compound on del(5q) stem cells, facilitating their disease progression. Different putative mechanisms have been discussed to explain AML progression: Gö hring et al.
8 presented evidence that pre-therapeutic telomere length was significantly shorter in those patients who ultimately transformed to AML than in those who did not. Data presented by Jadersten et al. 9 showed evidence that a number of patients with del(5q) MDS had p53 overexpression and mutations before lenalidomide administration. Those patients are prone to a higher apoptotic rate and may develop additional chromosomal aberrations in the course of the disease, leading to AML with complex karyotypes. Furthermore, a recent study in patients treated with lenalidomide for del(5q) disease achieving CCyR has shown that very early stem cells persisted with del(5q) karyotypic abnormality, despite achieving a complete hematological or cytogenetic response. 6 It has been speculated that continuous administration of lenalidomide may lead to selective pressure on stem cells that induces genomic instability, resulting in acute leukemia transformation. In fact, our study shows that some patients might remain in long-term CCyR (for example, 56 months, patient no. 1, data not shown) before they show reappearance of del(5q). As reappearance of del(5q) is not equivalent to transfusion dependence, a number of patients in our series remain transfusion-free for many years without being exposed to any medication. The CCyR rate in our patient sample is high (63%), resulting from a positive selection of patients who already had achieved transfusion independence. Interestingly, the achievement of CCyR and durability after lenalidomide interruption is not confined to patients with isolated del(5q). One patient in our series with a complex karyotype remains in CCyR for 76 months. Two patients had short lenalidomide exposure duration (28 and 104 days, respectively) and achieved transfusion independence; however, both patients relapsed within 24 months. In contrast, eight patients continued lenalidomide at least 6 months beyond achievement of CCyR. Seven of those patients remain transfusion independent at a median follow-up of 4.5 years since the start of transfusion independence. As all the three patients who relapsed with erythroid transfusion dependence in our series responded to re-exposure of lenalidomide, the concept of lenalidomide discontinuation could be offered at least to the very favorably responding group of patients who achieve CCyR and are treated for at least an additional 6 months.
One of our patients developed a complex karyotype without del(5q) chromosomal aberration 82 months after discontinuation of lenalidomide. This patient received multiple courses of fludarabine-containing chemotherapy regimens for follicular lymphoma. Complex karyotype evolution after fludarabine administration has been described. 10 The fact that del(5q) was not present in the karyotype at progression argues against progression of the initial MDS clone, and makes a causative role for lenalidomide unlikely. Of the other two patients with progressive disease, one presented with RAEB-1 and had a short lenalidomide exposure of o120 days. RAEB patients with del(5q) are known to have a higher AML progression rate than patients with marrow blasts o5%.
11 The third patient with initial marrow blasts of o5% achieved CCyR and had a cumulative exposure to lenalidomide of 12 months. P53 expression levels of this patient before therapy initiation are not available. In conclusion, lenalidomide interruption is safe and feasible in del(5q) MDS patients of low and intermediate-1 risk according to IPSS. Longest transfusion-free intervals are achieved in patients who are exposed to lenalidomide 6 months beyond complete cytogenetic remission. Lenalidomide should not be withdrawn prematurely in patients who achieve transfusion independence, as PCyR patients seem to have a higher relapse rate than CCyR patients, and only CCyR patients who continued treatment for at least 6 months beyond CCyR consistently seem to achieve very prolonged freedom from transfusion. Acute myeloid leukemia (AML) was the first disease in which leukemia-initiating cells (LICs) were identified using the NOD/ SCID (NS) xenotransplantation model. 1,2 These cells were originally reported to be rare. 2 Recent data in melanoma indicate that the frequency of tumor-initiating cells (TICs) increases dramatically when more permissive immunodeficient NS/ interleukin-2 receptor g-chain null (NSG) mice are used, 3 and contrary to the findings of Boiko et al., 4 TICs in melanoma might not be purified, 5 thus questioning the existence of TICs in melanoma. A study of pancreatic, non-small cell lung, and head and neck carcinoma shows that despite a 10-fold increase in the frequency of TICs in NSG compared with NS, the frequency of TICs remains low. 6 Recently, we demonstrated that LICs are also present in the CD34 þ CD38 þ fraction, 7 contrary to our initial findings. 2 We therefore re-investigated the issue of the frequency of LICs, comparing the originally used NS and the new NSG model.
Here, we first report that 14 AML samples, which did not engraft in NS mice, could still not engraft in NSG (see Supplementary Table 1a and Supplementary Figure 1) . Despite recent data, 8-10 including our own, showing that higher level of engraftment could be achieved in NSG compared with NS mice, the NSG model does not seem to be significantly more permissive, by enabling the engraftment of 'non-engrafter' AML samples tested originally in NS.
11 For patients with AML that engraft (see Supplementary Table 1b) , we estimated the LIC frequency using limiting dilution analysis. Figure 1 shows the results of 11 AML samples in which the frequency of LICs was compared side by side between NS and NSG ( Figure 1 and Supplementary Table 2) . It thus appears that the frequency of LICs varies between patients in both models. For patients in whom the frequency of LICs in NSG was higher than 1 in 50 000 cells (patients 6 to 11), the absolute number of LICs increased by 12-to 111-fold in NSG, compared with NS. This difference was less than five-fold for patients with lower frequency (LICs41 in 50 000; patients 1 to 5). Our results suggest that when lower numbers of cells were injected, a more pronounced difference was seen between the two models. Recently, we showed that the residual immune cells present in NS have a profound effect on the engraftment of antibody-labeled and -sorted CD38 þ cells. When using an anti-natural killer cell treatment or a more permissive NSG model, a drastic reduction of the clearance of these CD38 þ cells 7 was seen. Consequently, we decided to investigate the impact of residual immune cells on the difference in frequency observed. For four patients (5, 7, 8 and 9), we compared the LICs frequency using NS versus NS pre-treated with anti-122 antibody, versus NSG mice. The frequency of LICs between NS plus anti-CD122 and NSG was similar for patient 7 and 8. No difference was observed between the three mouse models for patient 5, but interestingly for patient 9, even when NS were pre-treated with anti-CD122, they were less sensitive than NSG in detecting LICs. Altogether, this indicates that differences in frequency of LICs between NS and NSG could be at least partially due to the presence of residual innate immune cells in NS (Supplementary Figure 2 and Supplementary Table 3) . It is also clear that despite differences in absolute frequency of LICs between the two mouse models, the same heterogeneity in the LICs frequency exist between patients. Patients can be classified as having low (patients 1 to 6 in NS and 1 to 5 in NSG) or high frequency of LICs (7 to 11 NS or 6 to 11 in NSG).
Recent data demonstrated the role of the complex CD47/ SIRP-a in controlling phagocytosis of normal cells by macrophages, and that both mouse and human myeloid leukemia cells have constitutive upregulation of CD47 to evade macrophage killing.
12 One possible explanation for the difference observed between 'non-engrafter' and 'engrafter' groups could be due to differences in the expression level of CD47. Supplementary Figure S3A shows that the mean fluorescence intensity of CD47 is variable in both groups with no significant difference between the two groups. We also show that for the 'engrafter' patients, the mean fluorescence intensity between the bulk mononuclear cells and the LIC fraction is equivalent (Supplementary Figure S3B ), confirming previous data. 12 We thus examine whether the level of CD47 expression could differ between low and high LICs frequency groups. As shown in Supplementary Figure S3C , CD47 level does not seem to correlate with LIC frequency. Additional experiments will be required to determine the precise requirement of CD47 on human AML-LICs.
One study reported a correlation between patient clinical outcome and the frequency of LICs quantified by phenotype, based on the percentage of the CD34 þ CD38 À fraction.
13
However, we recently reported that LICs are not restricted to this phenotypically defined fraction. 7, 14 We therefore tested in our cohort of patients, whether we could confirm this correlation. We observed a statistical difference in the overall survival between AML patients that engraft in NSG versus the ones that are unable to engraft, confirming our previous data in NS. 7 We nevertheless were unable to find a correlation between the high and low frequencies of LICs (even if we varied the cut-off
